Literature DB >> 18992012

Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.

Camilla Holmlund1, Hannu Haapasalo, Wei Yi, Olayinka Raheem, Thomas Brännström, Helena Bragge, Roger Henriksson, Håkan Hedman.   

Abstract

The three leucine-rich repeats and immunoglobulin-like domains (LRIG) genes encode integral membrane proteins. Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies. In astrocytic tumors, the subcellular distribution of LRIG proteins is associated with specific clinicopathological features and patient survival. The role of LRIG proteins in oligodendroglioma has not previously been studied. Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters. Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival. This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18992012     DOI: 10.1111/j.1440-1789.2008.00970.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  27 in total

Review 1.  The LRIG family: enigmatic regulators of growth factor receptor signaling.

Authors:  Catalina Simion; Maria Elvira Cedano-Prieto; Colleen Sweeney
Journal:  Endocr Relat Cancer       Date:  2014-09-02       Impact factor: 5.678

Review 2.  Urofacial syndrome: a genetic and congenital disease of aberrant urinary bladder innervation.

Authors:  Adrian S Woolf; Helen M Stuart; Neil A Roberts; Edward A McKenzie; Emma N Hilton; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

3.  Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma.

Authors:  Huaqiu Zhang; Qin Yan; Shutian Xu; Yibo Ou; Fei Ye; Baofeng Wang; Ting Lei; Dongsheng Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

4.  LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.

Authors:  Xi Zhang; Qian Song; Chunyan Wei; Jianqiang Qu
Journal:  Cell Stress Chaperones       Date:  2015-04-10       Impact factor: 3.667

5.  Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.

Authors:  Soma Ghasimi; Hannu Haapasalo; Mine Eray; Katariina Korhonen; Thomas Brännström; Håkan Hedman; Ulrika Andersson
Journal:  J Neurooncol       Date:  2012-04-08       Impact factor: 4.130

Review 6.  Genetics of human congenital urinary bladder disease.

Authors:  Adrian S Woolf; Helen M Stuart; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

7.  LRIG2 mutations cause urofacial syndrome.

Authors:  Helen M Stuart; Neil A Roberts; Berk Burgu; Sarah B Daly; Jill E Urquhart; Sanjeev Bhaskar; Jonathan E Dickerson; Murat Mermerkaya; Mesrur Selcuk Silay; Malcolm A Lewis; M Beatriz Orive Olondriz; Blanca Gener; Christian Beetz; Rita E Varga; Omer Gülpınar; Evren Süer; Tarkan Soygür; Zeynep B Ozçakar; Fatoş Yalçınkaya; Aslı Kavaz; Burcu Bulum; Adnan Gücük; Wyatt W Yue; Firat Erdogan; Andrew Berry; Neil A Hanley; Edward A McKenzie; Emma N Hilton; Adrian S Woolf; William G Newman
Journal:  Am J Hum Genet       Date:  2013-01-11       Impact factor: 11.025

8.  The negative regulation of miR-149-5p in melanoma cell survival and apoptosis by targeting LRIG2.

Authors:  Wenqi Chen; Jinhai Zhang; Huijuan Xu; Jie Dai; Xiaorong Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

9.  Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Authors:  Minhai Dong; Qungen Xiao; Jinyang Hu; Fangling Cheng; Po Zhang; Weifeng Zong; Qiaoying Tang; Xiaopeng Li; Feng Mao; Yue He; Xingjiang Yu; Feng Wan; Ting Lei; Dongsheng Guo; Baofeng Wang
Journal:  Cancer Gene Ther       Date:  2020-01-28       Impact factor: 5.987

10.  The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

Authors:  Mikael Johansson; Anaïs Oudin; Katja Tiemann; Amandine Bernard; Anna Golebiewska; Olivier Keunen; Fred Fack; Daniel Stieber; Baofeng Wang; Håkan Hedman; Simone P Niclou
Journal:  Neuro Oncol       Date:  2013-05-30       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.